Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites

Published: 01/05/2021

  • Centers for Disease Control and Prevention
Relevant To:
  • All Healthcare Organizations

The U.S. Centers for Disease Control and Prevention has issued interim considerations to assist COVID-19 vaccination sites prepare for the potential management of anaphylaxis events. According to the CDC, anaphylactic reactions in persons receiving the Pfizer-BioNTech COVID-19 vaccine outside of clinical trials have been reported. While these reports are further investigated, CDC considers a history of severe allergic reaction such as anaphylaxis to any vaccine or to any injectable therapy (e.g.

Sign Up for Free Trial